Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Helix BioPharma Corp.

HBP
Current price
0.78 CAD -0.01 CAD (-1.27%)
Last closed 0.82 CAD
ISIN CA4229101098
Sector Healthcare
Industry Biotechnology
Exchange Toronto Exchange
Capitalization 53 488 643 CAD
Yield for 12 month +212.00 %
1Y
3Y
5Y
10Y
15Y
HBP
21.11.2021 - 28.11.2021

Helix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, for the treatment of non-small cell lung cancer; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada. Address: 1055 West Georgia Street, Vancouver, BC, Canada, V6E 3P3

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.48 CAD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-13 014 CAD

Last Year

-12 013 CAD

Current Quarter

-3 004 CAD

Last Quarter

-3 004 CAD

Key Figures HBP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -9 234 530 CAD
Operating Margin TTM
PE Ratio
Return On Assets TTM -458.65 %
PEG Ratio
Return On Equity TTM -2220.62 %
Wall Street Target Price 3.48 CAD
Revenue TTM
Book Value -0.002 CAD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.05 CAD
Diluted Eps TTM -1.05 CAD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics HBP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History HBP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:5
Payout Ratio
Last Split Date 16.08.2024
Dividend Date

Stock Valuation HBP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -6.3589
Price Book MRQ 77.464

Financials HBP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators HBP

For 52 weeks

0.8 CAD 1.35 CAD
50 Day MA 1.19 CAD
Shares Short Prior Month 2 599
200 Day MA 1.08 CAD
Short Ratio 0.17
Shares Short 353
Short Percent